|
 |
Somani Hospital |
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical Trials & Research |
| |
1. A Randomized, Open Label, Non- Inferiority, Comparative, Multicentric Study Between Budesonide 200 µg in HFA propelled MDI And Beclomethasone Dipropionate 250 µg in HFA propelled MDI (Clenil® HFA 250 µg Spray) in a 12-week Treatment Period of Patients With Stable Persistent Asthma
2. A multicentre, randomized, open label, two-period, two-treatment, two-way crossover, bioequivalence study comparing Capecitabine Tablets USP 500 mg (Manufactured by: Dr. Reddy's Laboratories., India) to the reference listed drug Xeloda® (Capecitabine) Tablets 500 mg (Distributed by: Roche Laboratories Inc., New Jersey 07110) in Metastatic Breast Cancer or Colorectal Cancer patients under fed condition.
3. H9B-MC-BCDM: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy.
4. H9B-MC-BCDO: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy.
5. H9B-MC-BCDP: A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA).
6. Protocol Addendum H9B-MC-BCDM(1): A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy.
7. Fighting cervical cancer, FOGSI cervical cancer registry, a reaching the unreached FOGSI initiative 2010. A pap smear & HPV DNA & colposcopy based study.
8. Study No. - PT-101 : Phase 1 Study of Intravaginal Tamoxifen (PT-101): Randomized, double blind study of safety, pharmacokinetic (PK) and pharmacodynamics (PD) in menopausal patients with moderate to severe Vulvar and vaginal atrophy.
9. Title: Randomized, Comparative, Phase III Clinical Trial to Compare the Efficacy and Safety of Recombinant human Pegylated Granulocyte Colony Stimulating Factor (Peg G-CSF) Versus Granulocyte Colony Stimulating Factor (G-CSF) in Subjects with Nonmyeloid Malignancies Receiving Myelosuppressive Chemotherapy.
Click here to view Site SOP
|
| |
| |
| |
| |
| |
|
|
|
|
|
